India’s capital markets welcomed a new entrant from an underrepresented segment of healthcare as Gaudium IVF and Women Health made its stock market debut on February 27. The company listed at ₹83 per share on both NSE and BSE, representing a premium of about 5 percent over its IPO price band of ₹75–79. The listing performance, while positive, remained subdued compared with blockbuster healthcare listings seen in the past decade.

The ₹165-crore public issue had garnered moderate investor interest, receiving 7.27 times subscription during the February 20–24 bidding window. The stock’s debut also exceeded the flat grey market premium observed ahead of listing, indicating that formal market demand slightly outpaced informal expectations.

Gaudium’s listing is notable not for the size of the issue but for what it represents. The company becomes the first fertility care provider in India to access public equity markets, marking a potential turning point for assisted reproductive technology (ART) businesses seeking long-term capital for expansion. As fertility treatments gain social acceptance and demand rises due to delayed parenthood and lifestyle factors, the sector has evolved from a niche service to a scalable healthcare business.

Founded by Khanna, the company operates through a hub-and-spoke model comprising seven hubs and 28 spokes across multiple states. This model allows centralized expertise and laboratory infrastructure while maintaining local access points for patients — a structure commonly used by diagnostic chains and specialty healthcare providers to optimize costs and scale operations.

Proceeds from the fresh issue are earmarked primarily for expansion, with plans to establish 19 new IVF centres across India. The funds will also be used to repay debt and support general corporate purposes. This growth strategy underscores the fragmented nature of India’s fertility services market, where organized players still hold a relatively small share compared with standalone clinics.

Financially, the company has shown strong recent growth, albeit on a modest base. Revenue from operations rose to ₹70.72 crore in FY25 from ₹47.89 crore in FY24, while profit after tax nearly doubled to ₹19.13 crore from ₹10.31 crore. The sharp improvement in profitability suggests operating leverage as utilization improves across centres. However, the absolute scale remains small compared with listed hospital chains and diagnostic companies.

At the listing price, the company’s market capitalization stood at about ₹604 crore, placing it firmly in the small-cap category. For institutional investors, this implies limited liquidity and higher volatility, factors that often temper aggressive participation despite strong sectoral prospects.